絞り込み

16548

広告

A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib and Afatinib in Japanese Patients with Non-small Cell Lung Cancer.

著者 Fujiwara A , Yoshida M , Fujimoto H , Nakahara H , Ito K , Nishihama K , Yasuma T , Hataji O , Taguchi O , D'Alessandro-Gabazza CN , Gabazza EC , Kobayashi T
Oncol Res.2018 Jan 10 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (130view , 2users)

Full Text Sources

Miscellaneous

Tyrosine kinase inhibitors (TKIs) are very effective against non-small-cell lung cancer caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib and afatinib) for the therapy of non-small-cell lung cancer in Japan. Osimertinib can be indicated only against T790M (+) lung cancer as a second-line therapy. However, whether gefitinib, erlotinib or afatinib is most appropriate as a first-line therapy is still a controversial issue. The aim of this study was to compare the effectiveness of gefitinib, erlotinib and afatinib. We retrospectively reviewed the records of 310 patients with the diagnosis of EGFR mutation-associated non-small-cell lung cancer including 147 patients treated with EGFR TKIs. Time-to-treatment-failure and overall survival were evaluated. There were no significant differences in time-to-treatment-failure (gefitinib 9.2 months; erlotinib 9.8 months; afatinib 13.1 months) and overall survival (gefitinib 27.3 months; erlotinib 29.3 months; afatinib data not available) among non-small-cell lung cancer patients treated with the three different EGFR TKIs. Subgroup analysis showed that smoking status has a significant influence on both time-to-treatment-failure and overall survival. In conclusion this study showed comparable clinical efficacy of gefitinib, erlotinib and afatinib in Japanese patients with non-small cell lung cancer.
PMID: 29321093 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード